Business Context and Reporting Period
This Form 6-K filing by Quoin Pharmaceuticals, Ltd. covers the month of August 2022, with a report date of August 10, 2022. The Company is a clinical-stage biopharmaceutical company focused on developing treatments for rare skin diseases, currently advancing its lead asset, QRX003, for Netherton syndrome. The filing primarily details the completion of a public offering, a reverse split of American Depositary Shares (ADSs), and updates regarding Nasdaq listing compliance and going concern status.
Key Financial Metrics
- Capital Raised: The Company completed a public offering on August 9, 2022, resulting in gross proceeds of $16.8 million and net proceeds of approximately $15.0 million after fees and expenses.
- Offering Structure: The offering consisted of 2,210,000 ADSs at $5.00 per ADS and 1,150,000 Pre-Funded Warrants at $4.9999 per warrant. Each security included a Common Warrant with an exercise price of $5.00 per ADS.
- Revenue and Profit: The filing does not provide specific revenue or profit figures for the current period. The Company has no revenue from product sales since inception and expects to remain unprofitable for the foreseeable future.
- Liquidity: Prior to the offering, the Company faced substantial doubt regarding its ability to continue as a going concern due to the cancellation of a Series C Warrant that was expected to generate $9.5 million. The net proceeds from the August offering are intended to resolve this uncertainty.
- Debt: The filing references promissory notes issued in October 2020 but does not disclose the outstanding principal balance or specific debt terms in this summary.
Material Changes
- ADS Reverse Split: Effective August 1, 2022, the Company implemented a 1-for-12.5 reverse split of its ADSs, changing the ratio from 1 ADS representing 400 ordinary shares to 1 ADS representing 5,000 ordinary shares.
- Warrant Exercises: On August 2, 2022, Altium Growth Fund, LP exercised all outstanding warrants, resulting in the issuance of 399,999 ADSs. Additionally, the exercise price for Noteholder Warrants was reduced to $0.00 per ADS.
- Going Concern Status: The cancellation of the Series C Warrant in July 2022 removed an expected $9.5 million funding source, raising substantial doubt about the Company's ability to continue as a going concern. Management believes the completion of the August offering will allow for the modification of this qualification in the next quarterly filing.
Outlook, Risks, and Management Commentary
- Use of Proceeds: Net proceeds will be used for general corporate purposes, including operating expenses, research and development (clinical and pre-clinical testing), working capital, and potential acquisitions.
- Clinical Development: The Company's lead asset, QRX003, is in a randomized, double-blinded Phase 2 study in the U.S. for Netherton syndrome. The first clinical site opened in July 2022, with patient recruitment ongoing.
- Nasdaq Compliance:
- Stockholders' Equity: The Company received a notice of non-compliance with the $2.5 million minimum stockholders' equity requirement in April 2022. Management believes the August offering has restored compliance, pending Nasdaq confirmation.
- Minimum Bid Price: The Company received a notice in June 2022 regarding failure to maintain a $1.00 minimum bid price. It has until December 7, 2022, to regain compliance. As of the filing date, the closing bid price had exceeded $1.00 for eight consecutive business days.
- Risks: Key risks include the history of losses, need for additional capital, lack of product revenue, uncertainties in clinical trial results, and potential delisting from Nasdaq if compliance is not maintained.
Investor Verification Checklist
- Verify the final confirmation from Nasdaq regarding compliance with the $2.5 million stockholders' equity requirement.
- Monitor the closing bid price of ADSs to ensure it remains above $1.00 for the required 10 consecutive business days to satisfy the minimum bid price requirement by December 7, 2022.
- Review the next quarterly filing (Form 20-F or 6-K) to confirm the removal of the "going concern" qualification following the capital raise.
- Track the progress of the QRX003 clinical trial, specifically patient enrollment rates and the opening of additional clinical sites.
- Assess the dilution impact of the 3,360,000 ADSs issued in the offering plus the associated Common Warrants.